Investment Analysts’ Weekly Ratings Changes for Exagen (XGN)

Exagen (NASDAQ: XGN) recently received a number of ratings updates from brokerages and research firms:

• 8/7/2026 – Exagen had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 8/5/2026 – Exagen had its price target raised by TD Cowen from $8.00 to $10.00. They now have a “buy” rating on the stock.
• 8/5/2026 – Exagen had its “buy” rating reaffirmed by B. Riley Financial, Inc.. They now have a $12.00 price target on the stock, up from $8.00.
• 8/5/2026 – Exagen had its price target raised by BTIG Research from $8.00 to $9.00. They now have a “buy” rating on the stock.
• 6/24/2026 – Exagen is now covered by Roth Capital. They set a “buy” rating and a $8.00 price target on the stock.
• 6/24/2026 – Exagen was upgraded by Roth Capital to “strong-buy”.

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.